What is Global Cord Blood Corporation (CORBF) stock price today?

Global Cord Blood Corporation (CORBF) is currently trading at $0.95, down 0.11% today.

What is CORBF P/E ratio?

Global Cord Blood Corporation's P/E ratio is 1.56. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.

What is CORBF return on equity (ROE)?

Global Cord Blood Corporation's return on equity (ROE) is 10.82%. ROE measures net income relative to shareholders' equity. This is below the typical market range of roughly 12-15%.

What is Global Cord Blood Corporation's market cap?

Global Cord Blood Corporation has a market capitalization of $127.22M.

OTC · Medical - Diagnostics & Research

Global Cord Blood Corporation (CORBF) Stock

$0.95 -0.11% OTC: CORBF Healthcare

Valuation

Metric	Value
Price	$0.95
Market Cap	$127.22M
P/E Ratio	1.56
P/B Ratio	0.16
P/S Ratio	0.69
EPS (TTM)	$0.61
52-Week High	$1.75
52-Week Low	$0.20
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	10.82%
ROA	5.87%
ROCE	7.72%
Gross Margin	85.26%
Operating Margin	48.97%
Net Margin	40.30%
Debt/Equity	0.00
Current Ratio	10.73

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$937.0M	$987.0M	$1.2B	$1.2B	$1.2B
Operating Profit	$280.0M	$382.0M	$559.0M	$545.0M	$609.0M
Net Profit	$237.0M	$291.0M	$471.0M	$508.0M	$501.0M
EPS	$1.99	$2.40	$3.87	$4.18	$4.12
Op Margin	29.9%	38.7%	45.8%	47.0%	49.0%

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$5.8B	$6.6B	$7.2B	$7.9B	$8.5B
Total Liabilities	$2.7B	$3.1B	$3.3B	$3.5B	$3.6B
Cash	$4.3B	$5.0B	$5.5B	$6.1B	$6.7B
Borrowings	$0	$0	$3.0M	$2.0M	$0

Latest News

TSMC is moving in on Intel’s turf; Why Intel is up anyway Investing.com · Jul 30, 2026 U.S. economy slowed in second quarter as Iran war weighs on growth CBS News · Jul 30, 2026 Alphabet is $330 a Share: Could It Go To $420 This Year? 24/7 Wall St. · Jul 30, 2026 US economic growth slows to 1.5% in second quarter Yahoo Finance · Jul 30, 2026 Wine Country Colbert Group Ranked #1 Real Estate Team in Santa Rosa, CA by RealTrends ACCESS Newswire · Jul 30, 2026

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$819.0M	$792.0M	$624.0M	$631.0M	$614.0M
Investing Cash Flow	$-134.0M	$-61.0M	$-170.0M	$-41.0M	$-39.0M
Financing Cash Flow	$-2.0M	$-21.0M	$-4.0M	$-6.0M	$-8.0M
Net Cash Flow	$740.0M	$747.0M	$476.0M	$602.0M	$585.0M
Free Cash Flow	$752.0M	$761.0M	$600.0M	$610.0M	$594.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.20
EV / EBITDA	-8.84
FCF Yield	69.21%
Quick Ratio	10.66
Interest Coverage	—
Return 1Y	33.80%
Return 3Y	-13.64%
Return 5Y	-80.53%

Ownership

Insiders Held0.00%

Institutions Held13.40%

Institutions Float Held13.40%

Institutional Holder	Shares	Report Date
Rhumbline Advisers	13,362	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BIOQBioqual, Inc.	$32.50	+0.00%	-23.55	$29.07M	0.00%
CCELCryo-Cell International, Inc.	$4.30	-4.44%	-13.70	$34.67M	0.00%
LDDDLongduoduo Company Limited	$0.51	+0.00%	-43.59	$15.31M	0.00%

About Global Cord Blood Corporation

Global Cord Blood Corporation, headquartered in Central, Hong Kong, primarily offers umbilical cord blood preservation and related support services within the People's Republic of China. The company's operations include the comprehensive testing, processing, and long-term storage of cord blood samples for its individual clients. Additionally, it undertakes the examination, preparation, and storage of donated cord blood units, facilitating their use for matching purposes. As of March 31, 2022, the corporation oversaw the management of three distinct cord blood banks, located in Beijing municipality, Guangdong province, and Zhejiang province. The entity previously operated as China Cord Blood Corporation, adopting its current name in March 2018, and functions as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Global Cord Blood Corporation is headquartered in HK.

Global Cord Blood Corporation (CORBF) stock trades at $0.95 with a market capitalization of $127.22M. The stock is valued at a price-to-earnings (P/E) ratio of 1.56, price-to-book of 0.16, price-to-sales of 0.69. Over the past 52 weeks the stock has ranged between $0.20 and $1.75, and currently trades 45.7% below its 52-week high.

On profitability, Global Cord Blood Corporation generates a return on equity (ROE) of 10.82%, return on capital employed of 7.72%, an operating margin of 48.97%, a net profit margin of 40.30%.

Official website: www.globalcordbloodcorporation.com